Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Dose-finding Study in Platinum-Resistant Ovarian Cancer
- Conditions
- Recurrent Platinum-resistant Ovarian Cancer
- Interventions
- Drug: GSK2110183 in combination with carboplatin and paclitaxel
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 59
- Registration Number
- NCT01653912
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺Western Hospital, Footscray, Victoria, Australia
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 131
- Registration Number
- NCT01507194
- Locations
- 🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States
🇺🇸Precision Trials, Phoenix, Arizona, United States
🇺🇸Visions Clinical Research, Boynton Beach, Florida, United States
Single Dose Study of GSK1440115 in Patients With Asthma
- Conditions
- Asthma
- Interventions
- Drug: 1440115Drug: Placebo
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 12
- Registration Number
- NCT01424280
- Locations
- 🇦🇺
Investigational Site, New South Wales, Australia
Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)
- Conditions
- Post-Operative Nausea and Vomiting (PONV)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Accenture
- Target Recruit Count
- 55
- Registration Number
- NCT01290133
- Locations
- 🇦🇺
Investigational Site, Melbourne, Victoria, Australia
Repeat Dose Safety Study for Compound to Treat Asthma
- Conditions
- Asthma
- Interventions
- Drug: 1440115Drug: Placebo
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Accenture
- Registration Number
- NCT01202214
- Locations
- 🇦🇺
Investigational Site, Melbourne, Australia
- Prev
- 1
- 2
- Next
News
Moderna Partners with IBM to Advance mRNA Drug Discovery Through Quantum Computing and AI
Moderna has formed a strategic partnership with IBM to leverage quantum computing and generative artificial intelligence for advancing mRNA medicine discovery and development.
Healthcare Futurist: 'Culture of Happiness' and AI Integration Critical for Future Medical Success
Medical technologist Nick Webb emphasizes that future healthcare success will depend on creating a 'beautiful human experience' alongside clinical excellence, focusing on workforce and patient happiness.
Digital Transformation Reshapes Pharma Industry with $30B Investment Drive
The pharmaceutical industry is undergoing a major digital transformation accelerated by COVID-19, with companies expected to invest $30 billion in digital initiatives focusing on AI and Machine Learning technologies.